IUGNF - Imugene progresses onCARlytics solid tumour trial to combination arm

(NewsDirect)

Imugene Ltd(ASX:IMU) CEO Leslie Chong joins Proactive’s Jonathan Jackson in theProactive studio to discuss how the company has advanced its Phase 1onCARlytics solid tumour trial to combination arm treatment. Thetrial, known as OASIS, focuses on adult patients with advanced ormetastatic solid tumours, aiming to assess the safety and efficacy ofintratumoural (IT) injection and intravenous (IV) infusion, alone orcombined with the CD19 targeting drug blinatumomab (Blincyto® byAmgen).

TheCohort Review Committee (CRC) has reported no safety issues in theonCARlytics monotherapy lead-in study, prompting the clearance of thefirst cohort and the initiation of the combination arm.

The OASIS trialrepresents a pioneering approach in solid tumour treatment, combininga CD19-expressing oncolytic virus to prime tumours for attack byCD19-targeting therapeutics.

The trial's potential to shift the paradigm insolid tumour treatment is underlined by the promising advancements,with the combination arm set to explore the efficacy of onCARlytics inconjunction with blinatumomab. Imugene's progress in the OASIStrial signals a significant step forward in advancing novelimmunotherapies for solid tumour patients.

“It’s once again a credit to our team andcollaborators to see yet another study progressing positively and onschedule," Chong said. "Completion of this first monotherapyintratumoural cohort where ovarian, breast and melanoma patients weredosed paves the way for us to move into an important combinationdosing with Blincyto®, where we’ll be eager to see the greaterpotential of onCARlytics in targeting and eradicating solidtumours."

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2024 TheNewswire - All rights reserved.